NGM313 shows ‘acute and significant’ reductions in NASH markers

VIENNA — A single dose of NGM313 demonstrated improvements in multiple noninvasive markers of nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress 2019.
“In [a phase 1] study, we demonstrated a very favorable side-effect profile without any significant adverse events,” Alex M. DePaoli, MD, chief medical officer and vice president of translational research at NGM Biopharmaceuticals, said during his presentation. “What we saw in both of these studies was a very acute and significant reduction in triglycerides and this reduction was

Source link

Related posts

Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017


Guest commentary: My wedding during DDW shows positive work-life balance is possible


Gut bacteria can alter how well a medication works


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy